Treatment-Resistant Epilepsy
Our most established area of clinical research, including human evidence in children with severe, treatment-resistant epilepsy.
Learn moreResearch-driven biopharmaceutical company
Pioneering Precision Cannabinoid Medicine Since 2009
Better Cann Pharmaceutical is a research-driven biopharmaceutical company developing standardized, plant-derived therapeutics for complex neurological and chronic medical conditions.
- 2009
- Founded
- 15+
- Years of experience
- 5
- Therapeutic areas
Who we are
A research-driven biopharmaceutical company since 2009
Better Cann Pharmaceutical was founded in 2009 as a research-driven biopharmaceutical company focused on developing standardized cannabinoid-based therapeutics for complex medical conditions.
The company combines proprietary biological source genetics, formulation development, human clinical experience, and long-term treatment knowledge — with the goal of translating plant-derived science into reproducible, pharmaceutical-grade care.
Medicine first · Science-led
Translating plant-derived science into pharmaceutical precision.
What sets us apart
Built on four foundations
Clinical Evidence
Human clinical experience, including pediatric research, informs how our formulations are developed and studied.
Proprietary Genetics
Biological source genetics developed and stabilized since 2009 as controlled pharmaceutical raw material.
Pharmaceutical Consistency
Standardized active-compound profiles, documentation, and traceability from source material to formulation.
Treatment Continuity
More than a decade of accumulated treatment experience supports continuity of care for complex conditions.
Company highlights
More than a decade of experience
Figures shown below are editable, source-tracked content. Statements reflect company records and are labeled accordingly.
2009
Founded
Company record.
15+ yrs
Clinical & therapeutic experience
Since founding in 2009.
Human + pediatric
Clinical research
Including multi-center pediatric epilepsy research.
100,000+
Claimed cumulative patient reach
Company statement — cumulative reach of treatments and products; not independently audited.
Clinical research
Human Clinical Evidence in Treatment-Resistant Pediatric Epilepsy
Better Cann Pharmaceutical was among the early Israeli companies involved in multi-center clinical research involving children and adolescents with severe, treatment-resistant epilepsy.
Study focus
Children & adolescents with treatment-resistant epilepsy
- Population
- Pediatric
- Setting
- Major Israeli medical centers
- Status
- Human clinical experience
Where we focus
Therapeutic areas
We apply clinical experience and our biological source platform to conditions with significant unmet need.
Neurological Conditions
Exploring the role of standardized cannabinoid-based therapeutics across selected complex neurological conditions.
Learn moreRare Genetic Syndromes
Rare syndromes frequently present severe, treatment-resistant symptoms and profound unmet need.
Learn moreChronic Pain
Chronic pain is a widespread condition with substantial impact on quality of life and function.
Learn moreSupportive Oncology Care
Supportive care aims to help manage symptoms associated with cancer and its treatment.
Learn moreThe platform
Proprietary Biological Source Platform
Since 2009 we have developed and stabilized proprietary plant genetics as controlled pharmaceutical raw material — the foundation for standardized, reproducible therapeutic source materials.
- Controlled source genetics
- Chemical-profile consistency
- Active-compound reproducibility
- Long-term genetic selection
- Stable botanical inputs
- Medical formulation development
- 1Proprietary Genetics
- 2Controlled Cultivation
- 3Source Material Testing
- 4Extraction & Formulation
- 5Quality Review
- 6Clinical Development
- 7Therapeutic Product
Products & pipeline
From discovery to therapeutic product
A high-level view of development stages. Products are presented for scientific information and are not represented as approved medicines unless verified.
Discovery
Preclinical
Clinical Experience
Clinical Development
Regulatory Preparation
Partnership / Licensing
Global partnerships
Collaborate with Better Cann Pharmaceutical
Clinical Research
Collaborate on human clinical research programs and real-world evidence.
Licensing
License proprietary genetics, formulations, and know-how for defined markets.
Pharmaceutical Development
Co-develop standardized cannabinoid-based therapeutics.
Contract Manufacturing
Manufacturing collaboration around controlled source material and formulations.
Distribution
Distribution partnerships in regulated markets.
Technology Transfer
Transfer of process and quality know-how to qualified partners.
Quality & precision
Consistency you can document
Source-material consistency
Controlled genetics and cultivation aim to deliver reproducible active-compound profiles batch to batch.
Batch documentation
Each stage is documented to support traceability and review.
Laboratory testing
Analytical testing supports characterization of source material and formulations.
Traceability
A source-to-formulation chain links every therapeutic product back to its controlled inputs.
Controlled production
Production oversight is designed around consistency and quality objectives.
Regulatory documentation
Documentation practices are developed with regulatory readiness in mind.
Publications
Latest scientific publications
white paper· 2026
The Biological Source Platform: Standardization of Plant-Derived Pharmaceutical Inputs
Better Cann Pharmaceutical Scientific Affairs
Better Cann Pharmaceutical White Paper
Read moreApproved for Publication
corporate report· 2026
Better Cann Pharmaceutical Corporate & Scientific Overview
Better Cann Pharmaceutical
Corporate Report
Read moreApproved for Publication
peer reviewed· 2016
CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience
Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Bar Yosef O, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B
Seizure 35 (2016) 41–44
Read moreVerified